Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Secukinumab Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Secukinumab

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-benefit coverage of provider-administered intravenous secukinumab (Cosentyx) for Medicare Part B members. It establishes specialist, indication-specific clinical criteria, documentation requirements, approval durations, and coverage exclusions.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Secukinumab
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionSubmit documentation of prior NSAID failure or a qualifying contraindication and the applicable indication-specific clinical criteria with each authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial approval
    Up to 12 monthsExtension approval
    3 tender, 3 swollenPsoriatic arthritis activity threshold
    3Authorized specialist types

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    General requirements for all indications

    Covered when all of the following are met:

    All-indication requirements

    • FDA-approved use: Secukinumab IV is prescribed for an FDA-approved indication.
    • Specialist involvement: The medication is ordered by or provided in consultation with a rheumatologist, immunologist, or dermatologist.
    • Coverage and administration: The member has Medicare Part B coverage and meets the applicable criteria for a provider-administered drug.

    Ankylosing spondylitis and non-radiographic axial spondylarthritis

    Covered when all applicable criteria are met:

    • NSAID prerequisite

      • The member has failed at least one NSAID at the maximum tolerated dose.
      • The member has a contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
    • Clinical symptoms: Chart notes document significant clinical symptoms, including fatigue, spinal pain, arthralgia, inflammation of joints or tendons, morning stiffness duration, and therapy.
    • Peripheral arthritis treatment: When symptomatic peripheral arthritis is present, the member has had an insufficient response to at least one local corticosteroid injection.

      This requirement applies only when symptomatic peripheral arthritis is present.

    • DMARD exception:

    Psoriatic arthritis

    Covered when all applicable criteria are met:

    • Disease activity: The member has moderate to severe psoriatic arthritis demonstrated by at least three tender joints and at least three swollen joints on two separate occasions at least one month apart.>= 3 tender joints and >= 3 swollen joints on two separate occasions at least one month apart
    • NSAID prerequisite

      • The member has failed at least one NSAID at the maximum tolerated dose.
      • The member has a contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
    • Nonbiologic DMARD prerequisite

    Secukinumab is not covered when the member’s age, dose, dosing frequency, or treatment duration falls outside FDA-approved package labeling. Coverage is also excluded when secukinumab is used in combination with other biologics or when combination therapy is not supported by guidelines.

    Coding and Approval Parameters

    Drugs Requiring Prior Authorization under the medical benefitHCPCS
    J3590Cosentyx intravenous solution (secukinumab)
    Psoriatic arthritis joint activity
    Tender-joint thresholdAt least 3 tender joints
    Swollen-joint thresholdAt least 3 swollen joints
    Documentation frequencyBoth thresholds must be documented on two separate occasions at least one month apart
    Initial approval duration
    Applicable indicationsAnkylosing spondylitis and non-radiographic axial spondylarthritis
    Initial approval6 months
    Extension approval

    Provider Requirements and Authorization Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Secukinumab IV (J3590) under the medical benefit. Requests must document an FDA-approved indication, prescribing by or consultation with an appropriate specialist, and Medicare Part B coverage for this provider-administered drug.

    • FDA-approved indication
    • Rheumatologist, immunologist, or dermatologist involvement
    • Member has Medicare Part B coverage and meets the applicable criteria
    Step Therapy

    Document Required Conventional Therapy Trials

    For applicable indications, document failure of conventional therapy before requesting Secukinumab. An NSAID trial at the maximum tolerated dose is required unless the member has a qualifying contraindication; Psoriatic Arthritis also requires failure of an adequate trial of an eligible nonbiologic DMARD.

    • Ankylosing spondylitis/non-radiographic axial spondyloarthritis: failure of at least one NSAID unless contraindicated by cardiovascular disease, peptic ulcer disease, renal disease, or another qualifying contraindication

    Clinical Background

    Secukinumab (Cosentyx) is a human IgG1 monoclonal antibody that selectively binds interleukin-17A and inhibits its interaction with the IL-17A receptor. It is FDA approved for several conditions, including ankylosing spondylitis, psoriasis, and psoriatic arthritis. Because secukinumab may increase infection risk, members should be screened for immunologic and infectious disease before therapy is initiated.

    Initial Therapy

    General initial therapy

    Initial therapy requires all of the following general requirements:

    General initial authorization

    • Secukinumab IV is prescribed for an FDA-approved indication.
    • The medication is ordered by or provided in consultation with a rheumatologist, immunologist, or dermatologist.
    • The request is for a member with Medicare Part B coverage who meets the applicable criteria for a provider-administered drug.

    Initial therapy for axial spondyloarthritis

    For initial therapy, all of the following indication-specific criteria must be met:

    Initial axial spondyloarthritis therapy

    Continuation and Extension Therapy

    Continuation therapy

    Extensions are approved when all of the following are met:

    Continuation requirements

    • The member continues to benefit from secukinumab.
    • Response documentation

      • The member has the full desired response to secukinumab.
      • If secukinumab has not had the full desired effect or is considered a clinical failure, clinical rationale for continuing therapy is provided.

    Required Treatment Trials

    StepRequirementFailure or exception
    1
    Trial of at least one NSAID
    Document failure at the maximum tolerated dose, unless the member has a qualifying contraindication to NSAID therapy.
    StepRequirementFailure or exception
    2
    For psoriatic arthritis, trial of at least one nonbiologic DMARD: leflunomide, sulfasalazine, or methotrexate.
    Document failure to respond to an adequate trial. Pure axial manifestations do not require a nonbiologic DMARD trial; a methotrexate exception may apply when alcohol use makes methotrexate inappropriate and leflunomide and sulfasalazine are not clinically appropriate.
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Secukinumab
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionSubmit documentation of prior NSAID failure or a qualifying contraindication and the applicable indication-specific clinical criteria with each authorization request.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Approval ParametersProvider Requirements and Authorization RisksClinical BackgroundInitial TherapyContinuation and Extension TherapyRequired Treatment Trials
    A trial of a nonbiologic disease-modifying antirheumatic drug is not required for members with pure axial manifestations.
    The member has failed to respond to an adequate trial of at least one of the following nonbiologic DMARDs: leflunomide, sulfasalazine, or methotrexate.
  1. The member has pure axial manifestations, for which a trial of a nonbiologic DMARD is not required.
  2. When methotrexate is not appropriate because of alcohol use and both leflunomide and sulfasalazine are not clinically appropriate, chart notes document counseling to abstain from alcohol while taking methotrexate and the member's unwillingness to abstain.
  3. Up to 12 months when the member has continued benefit to therapy
    Initial approval duration
    Applicable indicationPsoriatic arthritis
    Initial approval6 months
    Extension approvalUp to 12 months when the member has continued benefit to therapy
    Extension approval
    Request typeExtension of secukinumab therapy
    Approval periodUp to 12 months
    Documentation requiredThe member must have continued benefit to therapy; clinical rationale is required when the full desired effect has not been achieved or treatment is considered a clinical failure
  4. Psoriatic arthritis: failure of at least one NSAID unless contraindicated
  5. Psoriatic arthritis: inadequate response to leflunomide, sulfasalazine, or methotrexate
  6. Pure axial manifestations do not require a nonbiologic DMARD trial
  7. Documentation Required

    Axial Spondyloarthritis Documentation

    For ankylosing spondylitis or non-radiographic axial spondyloarthritis, chart notes must support the NSAID failure, qualifying contraindication, or intolerance rationale and document the relevant clinical presentation and treatment history.

    • Document symptoms such as fatigue, spinal pain, arthralgia, joint or tendon inflammation, and morning-stiffness duration
    • Document insufficient response to a local corticosteroid injection when symptomatic peripheral arthritis is present
    • Pure axial manifestations do not require a nonbiologic DMARD trial
    Documentation Required

    Psoriatic Arthritis Documentation

    Psoriatic arthritis requests must document moderate-to-severe disease with at least three tender joints and three swollen joints on two separate occasions at least one month apart.

    • Record tender- and swollen-joint counts for both assessments
    • Assessments must be at least one month apart
    Documentation Required

    Methotrexate Exception Documentation

    When methotrexate is not appropriate because of alcohol use and leflunomide and sulfasalazine are not clinically appropriate, chart notes must document the required counseling and the member’s refusal to abstain from alcohol.

    • Document that the patient was counseled to abstain from alcohol while taking methotrexate
    • Document that the patient is unwilling to abstain from alcohol
    • Document why both leflunomide and sulfasalazine are not clinically appropriate
    Documentation Required

    Continuation Documentation

    Initial approval is limited to 6 months. Extension requests may be approved for up to 12 months when the member demonstrates continued benefit from therapy.

    • Document ongoing clinical benefit for each extension request
    Denial Risk

    Excluded Use or Combination Therapy

    Secukinumab is not covered when used outside FDA-approved package labeling or in prohibited combination therapy.

    • Age, dose, dosing frequency, or treatment duration outside FDA-approved labeling is excluded
    • Combination with other biologics is excluded
    • Combination therapy not supported by guidelines is excluded
    Denial Risk

    Insufficient Response Requires Rationale

    If Secukinumab has not produced the full desired effect or is considered a clinical failure, an extension request must include a clinical rationale explaining why treatment should continue despite the incomplete response.

    • Do not submit an incomplete-response or clinical-failure extension without individualized clinical rationale
    Denial Risk

    Unmet Authorization Criteria

    Requests may be denied when the required indication, specialist involvement, Medicare Part B coverage, or applicable clinical documentation is absent or does not support the criteria.

    • FDA-approved indication must be documented
    • Appropriate specialist prescribing or consultation must be documented
    • Medicare Part B coverage must be documented
    • Applicable NSAID, DMARD, symptom, injection, joint-count, and exception documentation must be included
  8. NSAID prerequisite

    • The member has failed at least one NSAID at the maximum tolerated dose.
    • The member has a qualifying contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
  9. Chart notes document significant clinical symptoms, including fatigue, spinal pain, arthralgia, inflammation of joints or tendons, morning stiffness duration, and therapy.
  10. When symptomatic peripheral arthritis is present, the member has had an insufficient response to at least one local corticosteroid injection.

    A nonbiologic DMARD trial is not required for pure axial manifestations.

  11. Initial therapy for psoriatic arthritis

    For initial therapy, all of the following indication-specific criteria must be met:

    Initial psoriatic arthritis therapy

    • Disease activity: The member has moderate to severe psoriatic arthritis demonstrated by at least three tender joints and at least three swollen joints on two separate occasions at least one month apart.>= 3 tender joints and >= 3 swollen joints on two separate occasions at least one month apart
    • NSAID prerequisite

      • The member has failed at least one NSAID at the maximum tolerated dose.
      • The member has a qualifying contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
    • Nonbiologic DMARD prerequisite

      • The member has failed to respond to an adequate trial of leflunomide, sulfasalazine, or methotrexate.
      • The member has pure axial manifestations, for which a nonbiologic DMARD trial is not required.
      • When methotrexate is not appropriate because of alcohol use and both leflunomide and sulfasalazine are not clinically appropriate, chart notes document counseling to abstain from alcohol while taking methotrexate and the member's unwillingness to abstain.